v3.26.3
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss
6 Months Ended
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 30, 2026
CNY (¥)
¥ / shares
shares
Jun. 30, 2025
CNY (¥)
¥ / shares
shares
Net revenues $ 27,265,664 ¥ 185,000,259 ¥ 174,469,851
Cost of revenues 23,540,807 159,726,732 146,152,450
Gross profit 3,724,857 25,273,527 28,317,401
Operating expenses:      
Sales and marketing expenses (including related party amounts of RMB882,786 and RMB557,426 (US$82,154) for the six months ended June 30, 2025 and 2026, respectively) 11,260,544 76,403,916 27,761,736
General and administrative expenses 11,123,286 75,472,617 10,494,487
Research and development expenses 15,662,791 106,273,600 1,479,909
Impairment loss on long-lived assets 67,282 456,520 2,041,299
Total operating expenses 38,113,903 258,606,653 41,777,431
Loss from operations (34,389,046) (233,333,126) (13,460,030)
Other expense, net:      
Other income 196,601 1,333,963 28,027
Other expense (8,713) (59,121) (130,291)
Interest expense (including related party amounts of RMB4,089,072 and RMB3,761,333 (US$554,352) for the six months ended June 30, 2025 and 2026, respectively) (902,182) (6,121,392) (6,471,198)
Government grants 11,292 76,619 148,000
Total other expense, net (703,002) (4,769,931) (6,425,462)
Loss before income tax (35,092,048) (238,103,057) (19,885,492)
Income tax expense (9,894) (67,131)
Net loss (35,101,942) (238,170,188) (19,885,492)
Accretion to redemption value of mezzanine equity (52,405,735)
Less: Net loss attributable to noncontrolling interests (1,235,737) (8,384,599) (960)
Net loss attributable to the Pomdoctor Limited’s ordinary shareholders (33,866,205) (229,785,589) (72,290,267)
Net loss (35,101,942) (238,170,188) (19,885,492)
Other comprehensive loss:      
Foreign currency translation adjustments, net of nil income taxes (342,737) (2,325,505) 7,106
Total comprehensive loss (35,444,679) (240,495,693) (19,878,386)
Less: comprehensive loss attributable to noncontrolling interests (1,235,737) (8,384,599) (960)
Comprehensive loss attributable to the Pomdoctor Limited’s ordinary shareholders $ (34,208,942) ¥ (232,111,094) ¥ (72,283,161)
Loss per share      
Basic | (per share) $ (1.46) ¥ (9.91) ¥ (11.46)
Diluted | (per share) $ (1.46) ¥ (9.91) ¥ (11.46)
Weighted average number of ordinary shares outstanding      
Basic (in Shares) 23,182,964 23,182,964 6,310,198
Diluted (in Shares) 23,182,964 23,182,964 6,310,198
Third Parties      
Net revenues $ 27,014,406 ¥ 183,295,449 ¥ 174,283,295
Related Party      
Net revenues $ 251,258 ¥ 1,704,810 ¥ 186,556